Faculty of Medicine
Library of the School of Health Sciences

2020-08-06

2020

Tservakis Ioannis

Ηλίας Γεωργάλας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Χρυσάνθη Κουτσανδρέα, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Δημήτριος Μπρούζας, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Δημήτριος Παπακωνσταντίνου, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Γεώργιος Κυμιωνής, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κλειώ Χατζηστεφάνου, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Δρούτσας, Επίκουρος Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ

Αποτελεσματικότητα και ασφάλεια του ενδοϋαλοειδικού εμφυτεύματος Δεξαμεθαζόνης (Οzurdex) για την αντιμετώπιση επίμονου οιδήματος της Ωχράς Κηλίδας εξαιτίας Θρόμβωσης Φλέβας Αμφιβληστροειδούς, σε ασθενείς με προηγηθείσα θεραπεία με anti – VEGF παράγοντα

Greek

Efficacy and safety of Dexamethasone intravitreal implant (Ozurdex) for the treatment of persistent Macular Edema secondary to Retinal Vein Occlusion in eyes previously treated with anti-Vascular Endothelial Growth Factors

In this Thesis we evaluated the safety and efficacy of repeated intravitreal dexamethasone implant (Ozurdex) injections administrated on an “as-needed” protocol for Retinal Vein Occlusion patients with Macular Edema, previously subjected to at least 5 anti-VEGF injections with poor or no response. In this prospective interventional case series we included a total of 23 eyes of 23 patients (13 Branch Retinal Vein Occlusions- BRVO and 10 Central Retinal Vein Occlusions-CRVO cases). The patients were followed every 2 months until month 12 with slit lamp examinations and SD-OCT and BCVA measurements. Minimum CRT values were achieved at 3.45 months after the first injection, and 2.46 months after the second injection of ozurdex in the BRVO group and at 2 months after both injections in the CRVO group. Best BCVA values were achieved at a mean of 4 months after the first injection, and 4 months after the second injection in the BRVO group and at 2 months after both injections in the CRVO group. Furthermore, in the CRVO group, neither the mean CRT nor BCVA improved significantly at 6 months unlike the BRVO group. Cataract progression was a rare event (2/23 eyes), while transient steroid-induced ocular hypertension (5/23 eyes) was managed successfully with IOP-lowering medication. We concluded that dexamethasone implant should be considered as an effective and safe alternative in patients with BRVO and CRVO who have failed anti-VEGF therapy. Shortening the re-injection interval especially for CRVO cases should be considered.

Health Sciences

Ozurdex, Branch Retinal Vein Occlusions - BRVO, Central Retinal Vein Occlusions - CRVO, Macular Edema, anti-VEGF

Yes

4

Yes

206

117

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2921230